Precision medicine has emerged as a new hope for cancer patients who have not gotten better with existing therapies. Precision medicine refers to personalized medical service that customizes treatments by analyzing the individual’s genetic information, medical history, and lifestyle. It makes treatments more efficient and lowers side effects.The Ministry of Health and Welfare and the Ministry
Celltrion’s Remsima (ingredient: infliximab), a therapy to treat autoimmune diseases, is showing a robust sales growth in the U.S. market, analysts said Wednesday.Distributed by Pfizer in the U.S., Remsima posted $34 million in revenue in the third quarter, up 47.8 percent from $23 million in the second quarter. Remsima sales in Europe also surged to $64 million in the third quarter, up 42.2 p
The government’s excessive intervention in the biopharmaceutical service market has deprived private players of a chance to grow as contract research organizations, or CROs, an expert said.CROs provide research services for drugmakers, biotech firms, and medical device manufacturers on a contract basis.Lee Jung-kue, CEO of Bridge Biotherapeutics, said the government had a vague role in
The Korean Association for Lung Cancer (KALC) has set about to emphasize the importance of the early diagnosis of lung cancer.Currently, the state-provided health check includes low-dose computed tomography (CT) to screen a lung cancer, but it is given only to people aged 55 or more with a high risk who have smoked a pack of cigarettes for more than 30 years.However, the KALC said, the lun
Stem cell researchers and related industry officials are paying attention to the recent news that Japan’s Kyoto University will begin a clinical trial for an experimental therapy for Parkinson’s disease using the so-called Induced Pluripotent Stem (IPS) cells.The university’s research team published a report in Nature on Aug. 30 that their treatment of implanting IPS cells, differentiated from
Korean diabetes patients might have come one step closer to getting a stem cell treatment, with Johnson & Johnson’s unit Janssen Biotech completing its patent registration on insulin-producing stem cell research in Korea.The company said its patent on the “differentiation of human embryonic stem cells” has been registered in the local market as of Sept. 29.According to Janssen Biotech,
South Korean biopharmaceutical firm Celltrion’s shares rose high in the local stock market, which resumed trading on Oct. 10 after a long holiday break.The company decided to move from tech-heavy Kosdaq to the main bourse Kospi at a meeting of shareholders on Sept. 29, just one day before the beginning of the holiday. Immediately after the stock market opened on Oct. 10, its shares soared. Aft
The Korean Diabetes Association unveiled its latest guidelines for diabetes therapy, citing newest clinical trials and documents, on Thursday.KDA made public its new guidelines on treating type-2 diabetes at a news conference on the sidelines of the 2017 International Congress of Diabetes and Metabolism at Grand Hilton Seoul Hotel, Seoul.It divided the guidelines into two types – one for o
A disposable short injection syringe is effective in insulin treatment, an expert said.The short injection needle can increase patients’ treatment compliance and prevent complications such as fat hypertrophia because of reuse, he added.Laurence Hirsch, vice president of BD Global’s diabetes medical affair division, made these and other points at a news conference in the Seoul Palace Hotel
An increasing number of Korean pharmaceutical firms have built smart factories, but their manufacturing performances are still at a “base level,” an expert said Wednesday.Hanmi Pharmaceutical, Korea United Pharm and Jeil Pharmaceutical recently established smart factories with advanced automation. The companies said their plants were armed with latest and most effective equipment that meets th
It is necessary for Korean pharmaceutical companies to distinguish big data from “large data” before introducing big data to increase the efficiency in developing new drugs, experts point out.They said the data that Korean pharmaceutical industry wants to use is not big data but merely large data in general."It is necessary to clarify whether they want big data or large data and have to un
Amid the intensifying competition to lower drug prices, market watchers predicted biosimilar products would continue to rake in profits thanks to the growth of overall markets.Remsima (infliximab), which has lowered its price below that of original products in the U.S, market, is showing slower tempo of market infiltration than expected, forcing some analysts to forecast that profits from bios
"Opdivo had gone ahead of Keytruda in America until last year, but Keytruda will sweep the U.S. market this year."So said Professor Bang Young-joo방영주 of Seoul National University Hospital서울대병원(Department of Hemato-oncology) while explaining the importance of biomarker to identify appropriate targets in developing new drugs and comparing the two immunity anticancer therapy -- Opdivo (compound:
With its main rival out of the race to develop sustained growth hormone therapy, Genexine saw its share price rose at the KOSDAQ market while most other bio stocks experienced a downtrend.Recently, the U.S. pharmaceutical Versartis failed to prove the noninferiority of its growth hormone “VRS-317” against the control group in phase 3 clinical trial. The company conducted the clinical trial of
Female researchers who majored in medicine and public health and took the lead in the government’s R&D projects last year accounted for only 31.8 percent of the total. Moreover, their per capita research expense on average was 140 million won ($124,000) lower than males'.According to a report titled “2016 analysis of national R&D project” released by Korea Institute of S&T Evaluation and Plann
Korea’s investment in the biomedical research and development lags far behind other advanced countries such as the U.S., a report showed.According to the report by the Hyundai Research Institute현대경제연구원 on the international comparison of the R&D by countries to prepare for “Fourth Industrial Revolution,” Korea’s R&D in the biomedical sector was 2.3 percent of that of the United States.K
Combination vaccines, which can prevent more viruses with fewer injections, have recently come to the market one after the other.According to a report released recently by Korea Centers for Disease Control and Prevention (KCDC)질병관리본부, the number of primary preventive injections of human papillomavirus (HPV) registered with its vaccination management system totaled 288,855 between July 20, 2016
Sillajen has emerged as the most successful case of the preferential listing on the KOSDAQ market, garnering revenue equivalent to 220 percent of its offering price, market sources say. A total of 11 bio-businesses have listed their shares on the KOSPI and KOSDAQ market since 2016, thanks to the government’s system that eased listed requirements for technology-oriented companies. Only four of
Genexine, which had brought anxiety to investors because of sudden stepdown of CEO Kyung Han-soo경한수, announced the interim result of phase 2 clinical trial for its growth hormone GX-H9, raising expectations about technology transfer.Genexine제넥신 had changed to the co-CEOs system of Seo You-seok 서유석 and Kyung Han-soo, but co-CEO Kyung stepped down on Aug. 31.In the phase 2 trial, GX-H9 s
The pharmaceutical industry is leading technological innovation and knowledge advancement among advanced industries and is being categorized as new growth engines in Korea, a report said Monday.The Korea Institute for Industrial Economics & Trade산업연구원 said in the report that there were 12 prospective “new growth industries” including pharmaceutical, advanced materials, smart cars, smart health